Cloning, expression, and purification of recombinant protein from a single synthetic multivalent construct of Mycobacterium tuberculosis

被引:9
作者
Fang, Chee-Mun
Zainuddin, Zainul F.
Musa, Mustaffa
Thong, Kwai-Lin [1 ]
机构
[1] Univ Malaya, Fac Sci, Inst Biol Sci, Kuala Lumpur 50603, Malaysia
[2] Univ Sci Malaysia, Sch Med Sci, Dept Immunol, Kubang Kerian, Kelantan, Malaysia
[3] Univ Sci Malaysia, Sch Hlth Sci, Kubang Kerian 16150, Kelantan, Malaysia
关键词
cloning; expression; Mycobacterium tuberculosis; multivalent; VacIII; inclusion body;
D O I
10.1016/j.pep.2005.12.007
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Tuberculosis remains a major infectious disease with over 8 million new cases and 2 million deaths annually. Therefore, a vaccine more potent than BCG is desperately needed. In this regard, an approximately 800 bp DNA encoding a mycobacterial synthetic gene designated as VacIII (containing ubiquitin gene UbGR and four immunogenic mycobacterial epitopes or genes of ESAT-6, Phos1, Hsp 16.3, and Mtb8.4) was sub-cloned into a bacterial expression vector of pRSET-B resulting in a 6x His-VaeIII fusion gene construction. This recombinant clone was over expressed in Escherichia coli BL-21 (DE-3). The expressed fusion protein was found almost entirely in the insoluble form (inclusion bodies) in cell lysate. The inclusion bodies were solubilized with 8 M urea and the recombinant protein was purified by Ni-NTA column and dialyzed by urea gradient dialysis. This method produced a relatively high yield of recombinant VacIII protein and the cloned VacIII gene offers the potential development of other vaccine formats such as DNA vaccine and recombinant vaccine. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:341 / 347
页数:7
相关论文
共 32 条
[1]  
ANDERSEN P, 1995, J IMMUNOL, V154, P3359
[2]   Virulence, immunogenicity, and protective efficacy of two recombinant Mycobacterium bovis bacillus calmette-gue'rin strains expressing the antigen ESAT-6 from Mycobacterium tuberculosis [J].
Bao, L ;
Chen, W ;
Zhang, HD ;
Wang, XY .
INFECTION AND IMMUNITY, 2003, 71 (04) :1656-1661
[3]   Epitope-specific antibody levels demonstrate recognition of new epitopes and changes in titer but not affinity during treatment of tuberculosis [J].
Bothamley, GH .
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2004, 11 (05) :942-951
[4]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[5]  
Brandt L, 1996, J IMMUNOL, V157, P3527
[6]   ESAT-6 subunit vaccination against Mycobacterium tuberculosis [J].
Brandt, L ;
Elhay, M ;
Rosenkrands, I ;
Lindblad, EB ;
Andersen, P .
INFECTION AND IMMUNITY, 2000, 68 (02) :791-795
[7]   Cytokine profile, HLA restriction and TCR sequence analysis of human CD4+ T clones specific for an immunodominant epitope of Mycobacterium tuberculosis 16-kDa protein [J].
Caccamo, N ;
Barera, A ;
Di Sano, C ;
Meraviglia, S ;
Ivanyi, J ;
Hudecz, F ;
Bosze, S ;
Dieli, F ;
Salerno, A .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2003, 133 (02) :260-266
[8]   Construction and deconstruction of bacterial inclusion bodies [J].
Carrió, MM ;
Villaverde, A .
JOURNAL OF BIOTECHNOLOGY, 2002, 96 (01) :3-12
[9]   EFFICACY OF BCG VACCINE IN THE PREVENTION OF TUBERCULOSIS - METAANALYSIS OF THE PUBLISHED LITERATURE [J].
COLDITZ, GA ;
BREWER, TF ;
BERKEY, CS ;
WILSON, ME ;
BURDICK, E ;
FINEBERG, HV ;
MOSTELLER, F .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (09) :698-702
[10]   Vaccination with the T cell antigen Mtb 8.4 protects against challenge with Mycobacterium tuberculosis [J].
Coler, RN ;
Campos-Neto, A ;
Ovendale, P ;
Day, FH ;
Fling, SP ;
Zhu, LQ ;
Serbina, N ;
Flynn, JL ;
Reed, SG ;
Alderson, MR .
JOURNAL OF IMMUNOLOGY, 2001, 166 (10) :6227-6235